NCT04663139View on ClinicalTrials.gov

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

June 26, 2021

Study Completion Date

June 26, 2021

Conditions
ObesityMetabolic Disease
Interventions
DRUG

Xla1

Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta)

DRUG

Placebo

Matching placebo

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors

Lead Sponsor

YSOPIA Bioscience
All Listed Sponsors
lead

YSOPIA Bioscience

INDUSTRY

NCT04663139 - Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults | Biotech Hunter | Biotech Hunter